var data={"title":"Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/contributors\" class=\"contributor contributor_credentials\">Peter H Schur, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/contributors\" class=\"contributor contributor_credentials\">Michael J Aminoff, MD, DSc</a></dd><dd><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/contributors\" class=\"contributor contributor_credentials\">Jonathan M Silver, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/contributors\" class=\"contributor contributor_credentials\">Janet L Wilterdink, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/contributors\" class=\"contributor contributor_credentials\">David Solomon, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 09, 2014.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Systemic lupus erythematosus (SLE) may involve the nervous system and present with a number of different neurologic and psychiatric syndromes (<a href=\"image.htm?imageKey=RHEUM%2F63649\" class=\"graphic graphic_table graphicRef63649 \">table 1</a>). These neuropsychiatric manifestations may mimic symptoms due to intercurrent illness, medication use, and functional disturbances (<a href=\"image.htm?imageKey=RHEUM%2F81577\" class=\"graphic graphic_table graphicRef81577 \">table 2</a>). The term lupus cerebritis refers to the neuropsychiatric manifestations of lupus that appear to have an organic rather than psychiatric basis, rather than a specific pathophysiologic mechanism.</p><p>Although it would be desirable to have diagnostic tests that establish a specific diagnosis of neuropsychiatric lupus, such tests do not exist. Thus, the approach to patients with neuropsychiatric symptoms consists of studies that establish the diagnosis of SLE, distinguish between organic and functional etiologies, and exclude symptoms not due to SLE. A typical workup for the patient with acutely altered behavior and mental status is outlined in Table 3 (<a href=\"image.htm?imageKey=RHEUM%2F77325\" class=\"graphic graphic_table graphicRef77325 \">table 3</a>).</p><p>Diagnostic testing, and the interpretation of such testing, in patients suspected of having neuropsychiatric manifestations of SLE are reviewed here. Details of the clinical neurologic and psychiatric manifestations of SLE are presented separately. (See <a href=\"topic.htm?path=neurologic-manifestations-of-systemic-lupus-erythematosus\" class=\"medical medical_review\">&quot;Neurologic manifestations of systemic lupus erythematosus&quot;</a> and <a href=\"topic.htm?path=neuropsychiatric-manifestations-of-systemic-lupus-erythematosus\" class=\"medical medical_review\">&quot;Neuropsychiatric manifestations of systemic lupus erythematosus&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">SEROLOGIC STUDIES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Serologic tests are typically used to help establish the diagnosis of SLE. The antinuclear antibody (ANA) titer is positive in virtually all patients with this disorder. However, the presence of ANA is not a very specific finding, and many non-SLE patients have symptoms such as headache or fatigue with only a weakly positive ANA. Serum levels of anti-DNA and anti-Sm antibodies and low levels of complement are useful in this setting to corroborate the diagnosis of SLE. (See <a href=\"topic.htm?path=diagnosis-and-differential-diagnosis-of-systemic-lupus-erythematosus-in-adults\" class=\"medical medical_review\">&quot;Diagnosis and differential diagnosis of systemic lupus erythematosus in adults&quot;</a>.)</p><p>In the patient with established SLE, an association between neuropsychiatric symptoms and specific antibodies has been demonstrated (by some) in a few circumstances [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/1-3\" class=\"abstract_t\">1-3</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antiphospholipid antibodies have been associated with cerebrovascular accidents, vascular dementia, seizures, thromboses, chorea, headache, and transverse myelitis [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/4-8\" class=\"abstract_t\">4-8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antiribosomal P antibodies have been associated with psychosis [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/9,10\" class=\"abstract_t\">9,10</a>] and with severe depression in some studies [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/4,11\" class=\"abstract_t\">4,11</a>]. However, others were unable to confirm an association of these psychiatric disorders with the presence of these antibodies [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/12\" class=\"abstract_t\">12</a>]. A meta-analysis published in 2006 reported that antiribosomal P antibodies have limited sensitivity and specificity (23 and 80 percent, respectively) for neuropsychiatric lupus and do not differentiate between subsets (eg, psychosis versus depression) [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/13\" class=\"abstract_t\">13</a>]. We do not use them in clinical practice to make a diagnosis of, nor to exclude, neuropsychiatric lupus. (See <a href=\"topic.htm?path=antiribosomal-p-protein-antibodies\" class=\"medical medical_review\">&quot;Antiribosomal P protein antibodies&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The roles, if any, of antineuronal, anti-neural tissue-specific, and anti-N-methyl-D-aspartate receptor (NMDA) antibodies are uncertain. Antibodies with these specificities are found in patients with many neuropsychiatric manifestations, including cognitive dysfunction and depression but studies of associations with specific deficits or mood disorders have been inconclusive or reached disparate conclusions [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/2,4,14-23\" class=\"abstract_t\">2,4,14-23</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antiganglioside antibodies have been observed in some with migraine and other neuropsychiatric symptoms [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/24\" class=\"abstract_t\">24</a>] as well as some patients with peripheral neuropathy [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/2\" class=\"abstract_t\">2</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antibodies to microtubule-associated protein 2 were found in a high percentage (63 to 76 percent) of patients with neuropsychiatric SLE in two small case series [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/25,26\" class=\"abstract_t\">25,26</a>]. This finding distinguished such patients from control groups, including those with SLE and no neuropsychiatric symptoms, other neurologic diseases (eg, multiple sclerosis, cerebrovascular disease), and healthy controls, in which these were found in only a few percent. In the latter study, antibodies to Hsp70-71 and triosephosphate isomerase were also found in 63 percent of 16 patients with neuropsychiatric SLE [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/26\" class=\"abstract_t\">26</a>].</p><p/><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PSYCHOLOGIC TESTING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Psychometric testing can be helpful to differentiate functional from organic disease. A battery of 11 or 12 tests, that require from one to four hours to complete; the shorter 11-test series is reasonably sensitive and specific, however, the latter is better able to detect selective cognitive deficits [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/27\" class=\"abstract_t\">27</a>]. These tests should be supplemented with a psychiatric interview when studies are equivocal [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/28,29\" class=\"abstract_t\">28,29</a>].</p><p>Computer assisted assessment of cognitive function has been used to follow the performance of patient with SLE. An example is the Automated Neuropsychological Assessment Metrics (ANAM) which was developed as a language-independent method for this purpose and has been validated in at least one study in patient with SLE [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/30\" class=\"abstract_t\">30</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">CEREBROSPINAL FLUID ANALYSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Routine evaluation of the cerebrospinal fluid (CSF) may be normal in patients with CNS lupus, except in cases of aseptic meningitis, vasculitis, and transverse myelitis. Some reports, however, have noted immunologic abnormalities including elevated levels of anti-DNA antibodies, IgG, oligoclonal banding, immune complexes, interleukin-6, the chemokine CXCL10, and markers of B-cell activation (eg, a proliferation-inducing ligand [APRIL] and B-cell activating factor of TNF family [BAFF]) which may roughly correlate with neuropsychiatric disease [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/4,31-34\" class=\"abstract_t\">4,31-34</a>].</p><p>One prospective study, for example, evaluated 52 patients hospitalized with diffuse or complex neuropsychiatric disease; all 52 had an abnormal CSF IgG index, oligoclonal bands, and increased CSF levels of antineuronal antibodies <span class=\"nowrap\">and/or</span> serum antiribosomal-P antibodies [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/4\" class=\"abstract_t\">4</a>]. Sensitivity for this triad of tests was 100 percent, while specificity was 86 percent. The authors concluded that these findings both suggest a role for autoantibodies in the pathogenesis of diffuse CNS lupus and that these tests can be followed serially since they appeared to correlate with clinical responses to therapy.</p><p>CSF levels of glial fibrillary acidic protein (GFAP), a product of neuroglia, and neurofilament triplet protein (NFL) are higher in those with CNS lupus than controls; mean elevations of three and seven fold, respectively [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/35\" class=\"abstract_t\">35</a>]. The increase in CSF concentrations of NFL was accompanied by generally higher intrathecal concentrations of interleukin-6 (IL-6), IL-8, oligoclonal immunoglobulins, and a higher CSF to serum albumin ratio. Levels of both GFAP and NFL were correlated with the degree of abnormality found on MRI. Further study of these putative markers of CNS lupus are needed. They are not specific for SLE and are elevated in other inflammatory CNS disorders.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">ELECTROENCEPHALOGRAPHY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately 80 percent of patients with active CNS lupus will have an abnormal routine EEG or EEG mapping [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/29,36\" class=\"abstract_t\">29,36</a>]. Diffuse slow wave activity is the pattern most typically associated with encephalopathy, while focal changes may be seen in patients with seizure disorders or focal neurologic problems.</p><p>The specificity of the EEG, however, is not as high as its sensitivity. Abnormal electroencephalograms have also been noted in patients with neurologic abnormalities with or without CNS lupus, and in those with active and inactive lesions. Evoked potentials and evoked potential mapping may be even more sensitive in detecting abnormalities [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/36\" class=\"abstract_t\">36</a>].</p><p>Quantitative EEG may also be an improvement over the conventional EEG. In one study of 52 patients, for example, the quantitative EEG was abnormal in 74 percent of patients judged to have neuropsychiatric SLE by other criteria, and in 28 percent of patients with no active evidence of CNS involvement [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/37\" class=\"abstract_t\">37</a>]. Overall sensitivity was 87 percent, and specificity was 75 percent. Quantitative EEG is not widely available.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">IMAGING STUDIES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of imaging methods are available for use in the diagnosis of neuropsychiatric SLE [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/38\" class=\"abstract_t\">38</a>]. CT scanning and magnetic resonance imaging (MRI) are the most useful.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">CT scanning</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CT scans are useful for detecting structural and focal abnormalities (such as <span class=\"nowrap\">infarcts/hypodense</span> areas, hemorrhage, tumors, cerebral calcification, abscess, and basilar meningitis) [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/38\" class=\"abstract_t\">38</a>]. Brain atrophy has been noted in some patients; this finding has been thought by some (but disputed by others) to reflect the effects of steroid therapy [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/6\" class=\"abstract_t\">6</a>] or age [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/4\" class=\"abstract_t\">4</a>]. We have seen brain atrophy out of proportion to a patient's age, and prior to steroid therapy.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Magnetic resonance imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>MRI is more sensitive than CT, and may reveal abnormalities that reflect focal neuropsychiatric lupus [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/39-41\" class=\"abstract_t\">39-41</a>]. However, MRI may also reveal white matter lesions or periventricular hyperintensities in patients with SLE who do not have neuropsychiatric symptoms [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/42\" class=\"abstract_t\">42</a>]. These white matter abnormalities may be difficult to interpret since they are present in 20 percent of the population younger than age 50, and in 90 percent of people older than age 70 [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/6,41\" class=\"abstract_t\">6,41</a>].</p><p>Numerous studies have investigated the usefulness of MRI in patients with SLE [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/43-48\" class=\"abstract_t\">43-48</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one series of 21 patients with SLE, 43 percent had high signal intensity, and 29 percent had large lesions; their presence correlated with disease activity as assessed by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/43\" class=\"abstract_t\">43</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another report of 40 randomly selected patients with SLE, 15 had abnormal findings consisting of multiple widespread small-sized infarcts or increased signal in the white matter on T2 weighted images [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/48\" class=\"abstract_t\">48</a>]. Only seven of these patients had neuropsychiatric symptoms. These small infarcts can mimic multiple sclerosis (<a href=\"image.htm?imageKey=RHEUM%2F75730\" class=\"graphic graphic_diagnosticimage graphicRef75730 \">image 1</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/41\" class=\"abstract_t\">41</a>]. They are frequently associated with antiphospholipid antibodies and livedo reticularis but not necessarily with neurologic symptoms [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/44\" class=\"abstract_t\">44</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with acute diffuse manifestations (seizures, psychosis, coma) may have longer T2 of the gray matter, suggesting cerebral edema [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/45\" class=\"abstract_t\">45</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acute, reversible lesions are characterized by the lack of discrete borders, intermediate intensity on T2-weighted images, intermediate size, a lacy filamentous pattern (which follows the gray-white matter junction along the sulci and gyri), and overlying or adjacent gray matter hyperintensity [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/38\" class=\"abstract_t\">38</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with SLE tend to have diminished cerebral and corpus callosal volume when compared to healthy persons; these MRI features, reported in a study of 155 patients, do not appear to be associated with cumulative glucocorticoid dose or the presence of antiphospholipid antibodies [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/49\" class=\"abstract_t\">49</a>]. The clinical significance of these findings are uncertain.</p><p/><p>MRI is the most useful neuroimaging study in patients with SLE, particularly in those with focal neurologic defects, seizures, chronic cognitive dysfunction, or the antiphospholipid syndrome and neurologic dysfunction [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/38\" class=\"abstract_t\">38</a>]; it is less useful in patients with affective disorders, confusional states, or headache. Although MRI frequently detects clinically silent lesions, we have found the correlation with neuropsychiatric symptoms to be quite good.</p><p>The role of advanced MRI techniques (functional MRI, MR spectroscopy, magnetization transfer imaging, diffusion tensor imaging) in evaluating patients with SLE is being investigated [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/50-52\" class=\"abstract_t\">50-52</a>]. </p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Single photon emission computed tomography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>While SPECT scanning has been advocated by some to be more sensitive than MRI for detecting brain abnormalities in patients with SLE [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/38\" class=\"abstract_t\">38</a>], published reports provide conflicting data. One study of 20 patients with SLE demonstrated SPECT scan abnormalities in 9 of 10 patients with overt CNS disease, and no SPECT scan abnormalities in 9 of 10 patients without CNS symptoms [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/53\" class=\"abstract_t\">53</a>]. In another study, 30 of 37 patients with NPSLE demonstrated brain SPECT scan abnormalities, specifically, reduced perfusion in the watershed area of the frontal lobes, the severity of which correlated with the severity of cognitive dysfunction [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/54\" class=\"abstract_t\">54</a>]. However, three other studies involving 94 patients did not demonstrate an association between SPECT scan abnormalities and neuropsychiatric manifestations of SLE [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/55-57\" class=\"abstract_t\">55-57</a>]. SPECT has poor specificity in differentiating neuropsychiatric from non-neuropsychiatric lupus [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/58\" class=\"abstract_t\">58</a>]. Our own unpublished observations also suggest that this modality does not correlate well with the clinical manifestations of CNS lupus, and should only be used for research purposes.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Other methods</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Numerous other studies have been used or studied in patients with SLE.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although angiography has been used historically to demonstrate vasculitis, it has limited sensitivity for detecting typical small vessel disease. Magnetic resonance angiography is also unable to accurately demonstrate these lesions [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/38,59\" class=\"abstract_t\">38,59</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>31P magnetic resonance spectroscopy (MRS) has been used to monitor changes in ATP and phosphocreatine during acute episodes of CNS lupus [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/60\" class=\"abstract_t\">60</a>], and proton NMR has been used to study anatomic changes in the brains of SLE patients with brain atrophy [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/61\" class=\"abstract_t\">61</a>]. Another technique, 1H MR spectroscopy, reportedly detects neurometabolic changes prior to irreversible neurologic damage [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/62\" class=\"abstract_t\">62</a>]. While it has been proposed that MRS can detect and measure brain injury that is not evident by MRI, can determine whether cognitive decline has an organic basis, and whether or not a lesion seen on MRI corresponds to a clinically relevant brain injury [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/58\" class=\"abstract_t\">58</a>], experience remains limited with these techniques [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/38\" class=\"abstract_t\">38</a>] and unless promising results are confirmed by larger studies, the use of MRS in the clinical evaluation of neuropsychiatric SLE in not recommended.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Position emission tomography (PET), using radiolabeled oxygen to assess brain cell metabolism, radiolabeled CO2 to evaluate cerebral vascular blood flow, and radiolabeled glucose, has demonstrated abnormalities of cell metabolism and regional blood flow in patients with SLE [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/63,64\" class=\"abstract_t\">63,64</a>]. However, this test is expensive, does not provide diagnostic information beyond that obtained with MRI, and is technically difficult to perform. PET is therefore <strong>not</strong> commonly used for diagnostic purposes [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/38\" class=\"abstract_t\">38</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Radionuclide brain scanning is generally not useful [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/6\" class=\"abstract_t\">6</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Limited evidence suggests that magnetization transfer imaging is more sensitive than MRI, particularly when quantifying brain damage, especially in patients with anti-cardiolipin antibodies [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/65,66\" class=\"abstract_t\">65,66</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Transcranial Doppler ultrasonography has been used to assess for signals indicative of microembolic matter in the cerebral circulation. In one study of 53 patients with SLE, ultrasonographic evidence of microemboli were detected much more frequently in the 25 patients with neuropsychiatric manifestations than those without such features [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/67\" class=\"abstract_t\">67</a>]. These signals were also more common in patients with SLE and elevated levels of anti-phospholipid antibodies.</p><p/><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">SUMMARY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Our recommended approach to the evaluation of neuropsychiatric disease in SLE is summarized in the algorithm in Table 3 (<a href=\"image.htm?imageKey=RHEUM%2F77325\" class=\"graphic graphic_table graphicRef77325 \">table 3</a>).</p><p class=\"headingAnchor\" id=\"H10837367\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editors of UpToDate, Inc. would like to acknowledge Shahram Khoshbin, MD, who contributed to earlier versions of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/1\" class=\"nounderline abstract_t\">Greenwood DL, Gitlits VM, Alderuccio F, et al. Autoantibodies in neuropsychiatric lupus. Autoimmunity 2002; 35:79.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/2\" class=\"nounderline abstract_t\">Sen&eacute;cal JL, Raymond Y. The pathogenesis of neuropsychiatric manifestations in systemic lupus erythematosus: a disease in search of autoantibodies, or autoantibodies in search of a disease? J Rheumatol 2004; 31:2093.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/3\" class=\"nounderline abstract_t\">Zandman-Goddard G, Chapman J, Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007; 36:297.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/4\" class=\"nounderline abstract_t\">West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995; 99:153.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/5\" class=\"nounderline abstract_t\">Asherson RA, Mercey D, Phillips G, et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 1987; 46:605.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/6\" class=\"nounderline abstract_t\">Boumpas DT, Austin HA 3rd, Fessler BJ, et al. Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995; 122:940.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/7\" class=\"nounderline abstract_t\">Toubi E, Khamashta MA, Panarra A, Hughes GR. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995; 99:397.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/8\" class=\"nounderline abstract_t\">Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30:985.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/9\" class=\"nounderline abstract_t\">Bonfa E, Golombek SJ, Kaufman LD, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987; 317:265.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/10\" class=\"nounderline abstract_t\">Nojima Y, Minota S, Yamada A, et al. Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51:1053.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/11\" class=\"nounderline abstract_t\">van Dam A, Nossent H, de Jong J, et al. Diagnostic value of antibodies against ribosomal phosphoproteins. A cross sectional and longitudinal study. J Rheumatol 1991; 18:1026.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/12\" class=\"nounderline abstract_t\">Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 2002; 41:1357.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/13\" class=\"nounderline abstract_t\">Karassa FB, Afeltra A, Ambrozic A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006; 54:312.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/14\" class=\"nounderline abstract_t\">West SG. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994; 20:129.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/15\" class=\"nounderline abstract_t\">Denburg SD, Behmann SA, Carbotte RM, Denburg JA. Lymphocyte antigens in neuropsychiatric systemic lupus erythematosus. Relationship of lymphocyte antibody specificities to clinical disease. Arthritis Rheum 1994; 37:369.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/16\" class=\"nounderline abstract_t\">Hanson VG, Horowitz M, Rosenbluth D, et al. Systemic lupus erythematosus patients with central nervous system involvement show autoantibodies to a 50-kD neuronal membrane protein. J Exp Med 1992; 176:565.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/17\" class=\"nounderline abstract_t\">Omdal R, Brokstad K, Waterloo K, et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005; 12:392.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/18\" class=\"nounderline abstract_t\">Husebye ES, Sthoeger ZM, Dayan M, et al. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64:1210.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/19\" class=\"nounderline abstract_t\">Lapteva L, Nowak M, Yarboro CH, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006; 54:2505.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/20\" class=\"nounderline abstract_t\">Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 2006; 54:2515.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/21\" class=\"nounderline abstract_t\">Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol 2006; 33:1553.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/22\" class=\"nounderline abstract_t\">Steup-Beekman G, Steens S, van Buchem M, Huizinga T. Anti-NMDA receptor autoantibodies in patients with systemic lupus erythematosus and their first-degree relatives. Lupus 2007; 16:329.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/23\" class=\"nounderline abstract_t\">Kimura A, Kanoh Y, Sakurai T, et al. Antibodies in patients with neuropsychiatric systemic lupus erythematosus. Neurology 2010; 74:1372.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/24\" class=\"nounderline abstract_t\">Galeazzi M, Annunziata P, Sebastiani GD, et al. Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological, and HLA class II gene associations. European Concerted Action on the Immunogenetics of SLE. J Rheumatol 2000; 27:135.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/25\" class=\"nounderline abstract_t\">Williams RC Jr, Sugiura K, Tan EM. Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2004; 50:1239.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/26\" class=\"nounderline abstract_t\">Lefranc D, Launay D, Dubucquoi S, et al. Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach. Arthritis Rheum 2007; 56:3420.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/27\" class=\"nounderline abstract_t\">Kozora E, Ellison MC, West S. Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum 2004; 51:810.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/28\" class=\"nounderline abstract_t\">Carbotte RM, Denburg SD, Denburg JA. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis 1986; 174:357.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/29\" class=\"nounderline abstract_t\">Rogers MP, Waterhouse E, Nagel JS, et al. I-123 iofetamine SPECT scan in systemic lupus erythematosus patients with cognitive and other minor neuropsychiatric symptoms: a pilot study. Lupus 1992; 1:215.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/30\" class=\"nounderline abstract_t\">Holliday SL, Navarrete MG, Hermosillo-Romo D, et al. Validating a computerized neuropsychological test battery for mixed ethnic lupus patients. Lupus 2003; 12:697.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/31\" class=\"nounderline abstract_t\">Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990; 33:644.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/32\" class=\"nounderline abstract_t\">McLean BN, Miller D, Thompson EJ. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Beh&ccedil;et's disease involving the nervous system. J Neurol Neurosurg Psychiatry 1995; 58:548.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/33\" class=\"nounderline abstract_t\">Okamoto H, Katsumata Y, Nishimura K, Kamatani N. Interferon-inducible protein 10/CXCL10 is increased in the cerebrospinal fluid of patients with central nervous system lupus. Arthritis Rheum 2004; 50:3731.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/34\" class=\"nounderline abstract_t\">George-Chandy A, Trysberg E, Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008; 10:R97.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/35\" class=\"nounderline abstract_t\">Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003; 48:2881.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/36\" class=\"nounderline abstract_t\">Khoshbin S, Levine L, Milrod L, et al. Cortical evoked potential mapping in complex partial seizures (abstract). Neurology 1984; 34:S219.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/37\" class=\"nounderline abstract_t\">Ritchlin CT, Chabot RJ, Alper K, et al. Quantitative electroencephalography. A new approach to the diagnosis of cerebral dysfunction in systemic lupus erythematosus. Arthritis Rheum 1992; 35:1330.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/38\" class=\"nounderline abstract_t\">Sibbitt WL Jr, Sibbitt RR, Brooks WM. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999; 42:2026.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/39\" class=\"nounderline abstract_t\">Jarek MJ, West SG, Baker MR, Rak KM. Magnetic resonance imaging in systemic lupus erythematosus patients without a history of neuropsychiatric lupus erythematosus. Arthritis Rheum 1994; 37:1609.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/40\" class=\"nounderline abstract_t\">Stimmler MM, Coletti PM, Quismorio FP Jr. Magnetic resonance imaging of the brain in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum 1993; 22:335.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/41\" class=\"nounderline abstract_t\">Scott TF, Hess D, Brillman J. Antiphospholipid antibody syndrome mimicking multiple sclerosis clinically and by magnetic resonance imaging. Arch Intern Med 1994; 154:917.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/42\" class=\"nounderline abstract_t\">Kozora E, West SG, Kotzin BL, et al. Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1998; 41:41.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/43\" class=\"nounderline abstract_t\">Taccari E, Sili Scavalli A, Spadaro A, et al. Magnetic resonance imaging (MRI) of the brain in SLE: ECLAM and SLEDAI correlations. Clin Exp Rheumatol 1994; 12:23.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/44\" class=\"nounderline abstract_t\">Ishikawa O, Ohnishi K, Miyachi Y, Ishizaka H. Cerebral lesions in systemic lupus erythematosus detected by magnetic resonance imaging. Relationship to anticardiolipin antibody. J Rheumatol 1994; 21:87.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/45\" class=\"nounderline abstract_t\">Sibbitt WL Jr, Brooks WM, Haseler LJ, et al. Spin-spin relaxation of brain tissues in systemic lupus erythematosus. A method for increasing the sensitivity of magnetic resonance imaging for neuropsychiatric lupus. Arthritis Rheum 1995; 38:810.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/46\" class=\"nounderline abstract_t\">McCune WJ, MacGuire A, Aisen A, Gebarski S. Identification of brain lesions in neuropsychiatric systemic lupus erythematosus by magnetic resonance scanning. Arthritis Rheum 1988; 31:159.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/47\" class=\"nounderline abstract_t\">Jacobs L, Kinkel PR, Costello PB, et al. Central nervous system lupus erythematosus: the value of magnetic resonance imaging. J Rheumatol 1988; 15:601.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/48\" class=\"nounderline abstract_t\">Cauli A, Montaldo C, Peltz MT, et al. Abnormalities of magnetic resonance imaging of the central nervous system in patients with systemic lupus erythematosus correlate with disease severity. Clin Rheumatol 1994; 13:615.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/49\" class=\"nounderline abstract_t\">Appenzeller S, Rondina JM, Li LM, et al. Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum 2005; 52:2783.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/50\" class=\"nounderline abstract_t\">Shapira-Lichter I, Vakil E, Litinsky I, et al. Learning and memory-related brain activity dynamics are altered in systemic lupus erythematosus: a functional magnetic resonance imaging study. Lupus 2013; 22:562.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/51\" class=\"nounderline abstract_t\">Zivadinov R, Shucard JL, Hussein S, et al. Multimodal imaging in systemic lupus erythematosus patients with diffuse neuropsychiatric involvement. Lupus 2013; 22:675.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/52\" class=\"nounderline abstract_t\">Zimny A, Szmyrka-Kaczmarek M, Szewczyk P, et al. In vivo evaluation of brain damage in the course of systemic lupus erythematosus using magnetic resonance spectroscopy, perfusion-weighted and diffusion-tensor imaging. Lupus 2014; 23:10.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/53\" class=\"nounderline abstract_t\">Rubbert A, Marienhagen J, Pirner K, et al. Single-photon-emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum 1993; 36:1253.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/54\" class=\"nounderline abstract_t\">Driver CB, Wallace DJ, Lee JC, et al. Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008; 59:332.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/55\" class=\"nounderline abstract_t\">Emmi L, Bramati M, De Cristofaro MT, et al. MRI and SPECT investigations of the CNS in SLE patients. Clin Exp Rheumatol 1993; 11:13.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/56\" class=\"nounderline abstract_t\">Nossent JC, Hovestadt A, Sch&ouml;nfeld DH, Swaak AJ. Single-photon-emission computed tomography of the brain in the evaluation of cerebral lupus. Arthritis Rheum 1991; 34:1397.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/57\" class=\"nounderline abstract_t\">Waterloo K, Omdal R, Sj&ouml;holm H, et al. Neuropsychological dysfunction in systemic lupus erythematosus is not associated with changes in cerebral blood flow. J Neurol 2001; 248:595.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/58\" class=\"nounderline abstract_t\">Govoni M, Castellino G, Padovan M, et al. Recent advances and future perspective in neuroimaging in neuropsychiatric systemic lupus erythematosus. Lupus 2004; 13:149.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/59\" class=\"nounderline abstract_t\">Harris KG, Yuh WT. Intracranial vasculitis. Neuroimaging Clin N Am 1994; 4:773.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/60\" class=\"nounderline abstract_t\">Griffey RH, Brown MS, Bankhurst AD, et al. Depletion of high-energy phosphates in the central nervous system of patients with systemic lupus erythematosus, as determined by phosphorus-31 nuclear magnetic resonance spectroscopy. Arthritis Rheum 1990; 33:827.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/61\" class=\"nounderline abstract_t\">Sibbitt WL Jr, Haseler LJ, Griffey RH, et al. Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy. AJNR Am J Neuroradiol 1994; 15:923.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/62\" class=\"nounderline abstract_t\">Axford JS, Howe FA, Heron C, Griffiths JR. Sensitivity of quantitative (1)H magnetic resonance spectroscopy of the brain in detecting early neuronal damage in systemic lupus erythematosus. Ann Rheum Dis 2001; 60:106.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/63\" class=\"nounderline abstract_t\">Pinching AJ, Travers RL, Hughes GR, et al. Oxygen-15 brain scanning for detection of cerebral involvement in systemic lupus erythematosus. Lancet 1978; 1:898.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/64\" class=\"nounderline abstract_t\">Weiner SM, Otte A, Schumacher M, et al. Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis 2000; 59:377.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/65\" class=\"nounderline abstract_t\">Steens SC, Admiraal-Behloul F, Bosma GP, et al. Selective gray matter damage in neuropsychiatric lupus. Arthritis Rheum 2004; 50:2877.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/66\" class=\"nounderline abstract_t\">Steens SC, Bosma GP, Steup-Beekman GM, et al. Association between microscopic brain damage as indicated by magnetization transfer imaging and anticardiolipin antibodies in neuropsychiatric lupus. Arthritis Res Ther 2006; 8:R38.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/67\" class=\"nounderline abstract_t\">Kumral E, Evyapan D, Keser G, et al. Detection of microembolic signals in patients with neuropsychiatric lupus erythematosus. Eur Neurol 2002; 47:131.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4865 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H11\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">SEROLOGIC STUDIES</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PSYCHOLOGIC TESTING</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">CEREBROSPINAL FLUID ANALYSIS</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">ELECTROENCEPHALOGRAPHY</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">IMAGING STUDIES</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">CT scanning</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Magnetic resonance imaging</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Single photon emission computed tomography</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Other methods</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">SUMMARY</a></li><li><a href=\"#H10837367\" id=\"outline-link-H10837367\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"NEURO/4865|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=RHEUM/75730\" class=\"graphic graphic_diagnosticimage\">- Lupus sclerosis MRI</a></li></ul></li><li><div id=\"NEURO/4865|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=RHEUM/63649\" class=\"graphic graphic_table\">- Sx neuropsychiatric lupus</a></li><li><a href=\"image.htm?imageKey=RHEUM/81577\" class=\"graphic graphic_table\">- Causes neuropsychiatric lupus</a></li><li><a href=\"image.htm?imageKey=RHEUM/77325\" class=\"graphic graphic_table\">- Dx neuropsychiatric lupus</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antiribosomal-p-protein-antibodies\" class=\"medical medical_review\">Antiribosomal P protein antibodies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-differential-diagnosis-of-systemic-lupus-erythematosus-in-adults\" class=\"medical medical_review\">Diagnosis and differential diagnosis of systemic lupus erythematosus in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neurologic-manifestations-of-systemic-lupus-erythematosus\" class=\"medical medical_review\">Neurologic manifestations of systemic lupus erythematosus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neuropsychiatric-manifestations-of-systemic-lupus-erythematosus\" class=\"medical medical_review\">Neuropsychiatric manifestations of systemic lupus erythematosus</a></li></ul></div></div>","javascript":null}